Sugi Predict

Sugi Predict / Compounds / SCHEMBL758271

SCHEMBL758271

SCHEMBL758271

CC(=O)c1ccc(NC(=O)CN)cc1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.62
▸ ALDH1A1 P00352 3/20 0.62
▸ NPC1 O15118 6/20 0.60
▸ SMN1; SMN2 Q16637 4/20 0.60
▸ MAPK1 P28482 1/20 0.58
▸ CA1 P00915 2/20 0.56
▸ CA2 P00918 2/20 0.56
▸ RAB9A P51151 4/20 0.55
▸ TAAR1 Q96RJ0 1/20 0.55
▸ MEN1 O00255 3/20 0.54
▸ KMT2A Q03164 3/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54
▸ POLB P06746 1/20 0.54
▸ BLM P54132 1/20 0.54
▸ HTT P42858 1/20 0.53
▸ NLRP1 Q9C000 1/20 0.53
▸ ATM Q13315 1/20 0.53
▸ CA12 O43570 1/20 0.51
▸ CA9 Q16790 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11643029 0.90 MAPT (0.59) MAPTALDH1A1NPC1SMN1; SMN2MAPK1
SCHEMBL11639528 0.90 HPGD (0.59) MAPTALDH1A1NPC1SMN1; SMN2MAPK1
SCHEMBL11642356 0.89 CA1 (0.62) MAPTALDH1A1NPC1SMN1; SMN2MAPK1
SCHEMBL11641865 0.87 MAPT (0.50) MAPTALDH1A1NPC1SMN1; SMN2MAPK1
SCHEMBL31570085 0.86 MAPT (0.64) MAPTALDH1A1NPC1SMN1; SMN2MAPK1
SCHEMBL18602214 0.85 MAPT (0.68) MAPTALDH1A1NPC1SMN1; SMN2MAPK1
SCHEMBL27465349 0.85 CA1 (0.53) MAPTALDH1A1NPC1SMN1; SMN2CA1
SCHEMBL15061798 0.84 CA1 (0.59) MAPTALDH1A1NPC1SMN1; SMN2CA1
SCHEMBL1663647 0.82 CA2 (0.58) ALDH1A1CA1CA2TAAR1MEN1
SCHEMBL6934236 0.82 CA1 (0.58) MAPTALDH1A1SMN1; SMN2MAPK1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160355859-A1 TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES NOVO NORDISK A/S (DK) 2016-12-08 — — US claimed
CN-103215328-B The joint of transglutaminase mediated peptide 诺和诺德医疗保健公司 2016-08-03 — — CN claimed
CN-103215328-A Transglutaminase mediated conjugation of peptides NOVO NORDISK AS 2013-07-24 — — CN claimed
EP-2033662-B1 Transglutaminase mediated conjugation of peptides NOVO NORDISK HEALTHCARE AG (CH) 2012-10-17 — — EP claimed
EP-2368579-A1 Transglutaminase mediated conjugation of peptides Novo Nordisk Health Care AG (CH) 2011-09-28 — — EP claimed
US-20100009917-A1 Modulating Enzymatic Processes by Addition of Diolcontaining Substances NOVO NORDISK HEALTH CARE AG (CH) 2010-01-14 — — US claimed
CN-101617053-A The method that contains the material regulatory enzyme of glycol by interpolation NOVO NORDISK HEALTHCARE AG 2009-12-30 — — CN claimed
EP-2121952-A1 MODULATING ENZYMATIC PROCESSES BY ADDITION OF DIOLCONTAINING SUBSTANCES Novo Nordisk Health Care AG (CH) 2009-11-25 — — EP claimed
US-20090264366-A1 Transglutaminase Mediated Conjugation of Peptides NOVO NORDISK HEALTHCARE AG (CH) 2009-10-22 — — US claimed
EP-2033662-A1 Transglutaminase mediated conjugation of peptides Novo Nordisk Health Care AG (CH) 2009-03-11 — — EP claimed
WO-2008101957-A1 MODULATING ENZYMATIC PROCESSES BY ADDITION OF DIOLCONTAINING SUBSTANCES NOVO NORDISK HEALTH CARE AG (DK) 2008-08-28 — — WO claimed
JP-2007518747-A — — 2007-07-12 — — JP claimed
US-20070105770-A1 Transglutaminase mediated conjugation of peptides NOVO NORDISK A/S (DK) 2007-05-10 — — US claimed
CN-1909930-A Transglutaminase mediated conjugation of peptides NOVO NORDISK AS (DK) 2007-02-07 — — CN claimed
EP-1708755-A2 TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES NOVO NORDISK A/S (DK) 2006-10-11 — — EP claimed
WO-2005070468-A2 TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES NOVO NORDISK A/S (DK) 2005-08-04 — — WO claimed
EP-2842576-B1 Transglutaminase mediated conjugation of peptides NOVO NORDISK HEALTHCARE AG (CH) 2017-06-28 — — EP disclosed
EP-2560690-B1 CYCLOPENTAPEPTIDE DERIVATIVES AND USES THEREOF Technische Universität München (DE) 2017-03-08 — — EP disclosed
EP-1708755-A2 TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES NOVO NORDISK A/S (DK) 2006-10-11 — — EP disclosed
WO-2005070468-A2 TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES NOVO NORDISK A/S (DK) 2005-08-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264366-A1 Transglutaminase Mediated Conjugation of Peptides TGM2, TGM3, TGM1 MAPT 2315/4885ALDH1A1 3543/4885NPC1 4732/4885
US-20100009917-A1 Modulating Enzymatic Processes by Addition of Diolcontaining Substances HSD17B14, CES2, PNLIP MAPT 4178/4885ALDH1A1 426/4885NPC1 2475/4885
US-20070105770-A1 Transglutaminase mediated conjugation of peptides TGM2, TGM3, TGM1 MAPT 2315/4885ALDH1A1 3543/4885NPC1 4732/4885
US-20160355859-A1 TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES TGM2, TGM3, TGM1 MAPT 2315/4885ALDH1A1 3543/4885NPC1 4732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.